Anti-GAD antibody-associated epilepsy in pregnancy

Area of Science:

• Neurology
• Immunology
• Reproductive Medicine

Background:

• Anti-GAD antibody-associated epilepsy (AAE) is a rare neurological disorder caused by autoantibodies to glutamic acid decarboxylase 65 (GAD65).
• AAE typically affects women of childbearing age, presenting with refractory seizures.
• Pregnancy in women with AAE poses unique management challenges due to potential risks to both mother and fetus.

Purpose of the Study:

• To describe the management of a pregnant woman with anti-GAD antibody-associated epilepsy.
• To evaluate the efficacy and safety of anti-seizure medications (ASM) and intravenous immunoglobulin (IVIG) during pregnancy.
• To report on maternal and neonatal outcomes in this specific case.

Main Methods:

• Case report of a woman in her first pregnancy diagnosed with AAE.
• Treatment involved a combination of ASMs and IVIG, with dose adjustments based on seizure frequency and drug levels.
• Monitoring included maternal seizure control, drug levels, and fetal well-being.
• Neonatal assessment included anti-GAD antibody testing and neurological examination.

Main Results:

• The patient's AAE was managed throughout pregnancy with escalating doses of ASMs and IVIG.
• Increased seizure frequency necessitated medication adjustments as pregnancy progressed.
• Delivery of a healthy neonate occurred at 38 weeks' gestation.
• Intrahepatic cholestasis, possibly linked to azathioprine, led to labor induction.
• Neonatal anti-GAD antibody levels were tested, with follow-up planned for developmental assessment.

Conclusions:

• Management of AAE during pregnancy is feasible with a combination of ASMs and IVIG.
• Close monitoring and dose escalation of ASMs are crucial as pregnancy advances.
• Potential drug-related complications, such as intrahepatic cholestasis, require vigilance.
• Neonatal outcomes, including the significance of passively transferred antibodies, warrant further follow-up.